昆仙胶囊联合缬沙坦治疗糖尿病肾病临床研究  

Clinical Study of Kunxian Capsules Combined with Valsartan in Treating Diabetic Nephropathy

作　　者：石新慧 任东升[1] 鲁冰[1] 谷裕 徐光 SHI Xinhui;REN Dongsheng;LU Bing;GU Yu;XU Guang(Nephrology Department,Nanyang Central Hospital,Nanyang Henan 473005,China)

机构地区：[1]南阳市中心医院肾病内科,河南南阳473005

出　　处：《新中医》2024年第24期70-74,共5页New Chinese Medicine

基　　金：南阳市科技攻关计划项目(KJGG144)。

摘　　要：目的:观察昆仙胶囊联合缬沙坦治疗对糖尿病肾病患者肾间质纤维化、免疫-炎症因子及血液流变学的影响。方法:选取2022年3月—2023年3月南阳市中心医院肾病内科收治的糖尿病肾病患者120例,随机分为昆仙胶囊组和缬沙坦组各60例。缬沙坦组予口服缬沙坦治疗,昆仙胶囊组在缬沙坦组治疗方案的基础上加用昆仙胶囊治疗,2组均连续治疗2个月。观察并记录2组肾间质纤维化指标[转化生长因子-β(TGF-β1)、血管内皮生长因子(VEGF)、血管紧张素Ⅱ(AngⅡ)]、炎症因子[C-反应蛋白(CRP)、肿瘤坏死因子(TNF-α)及白细胞介素6(IL-6)]、血液流变学指标(红细胞聚集指数、血浆黏度、低切黏度、高切黏度)、中医证候积分及临床疗效。结果:治疗后,2组CRP、TNF-α、IL-1、α-SMA、AngⅡ、TGF-β水平,中医证候积分均较治疗前下降,差异均有统计学意义(P<0.05);昆仙胶囊组以上各项指标值均低于缬沙坦组。治疗后,2组红细胞聚集指数、血浆黏度、低切黏度、高切黏度均较治疗前降低,昆仙胶囊组以上各项指标值均低于缬沙坦组,差异均有统计学意义(P<0.05)。昆仙胶囊组总有效率93.33%,缬沙坦组80.00%,差异有统计学意义(P<0.05)。结论:昆仙胶囊联合缬沙坦治疗糖尿病肾病,可有效抑制肾实质纤维化及炎症反应,降低血液黏度,改善患者生活质量。Objective:To observe the effect of Kunxian Capsules combined with Valsartan on renal interstitial fibrosis,immune-inflammatory factors and hemorheology in patients with diabetic nephropathy.Methods:A total of 120 patients with diabetic nephropathy admitted to the Nephrology Department of Nanyang Central Hospital from March 2022 to March 2023 were randomly divided into the Kunxian Capsules group and the Valsartan group,with 60 patients in each group.The Valsartan group received Valsartan treatment orally,and the Kunxian Capsules group received Kunxian Capsules in addition to the Valsartan group treatment plan.Both groups were treated continuously for two months.The renal interstitial fibrosis indicators[transforming growth factor-β1(TGF-β1),vascular endothelial growth factor(VEGF),and angiotensinⅡ(AngⅡ)],inflammatory factors[C-reactive protein(CRP),tumor necrosis factor-α(TNF-α),and interleukin-6(IL-6)],hemorheological indicators(red blood cell aggregation indexes,plasma viscosity,low-shear viscosity,and high-shear viscosity),traditional Chinese medicine syndrome scores,and clinical effects were observed and recorded in the two groups.Results:After treatment,the levels of CRP,TNF-α,IL-1,α-SMA,AngⅡ,and TGF-β1,and traditional Chinese medicine syndrome scores in the two groups were decreased when compared with those before treatment,with differences being significant(P<0.05);the values of the above indicators in the Kunxian Capsules group were lower than those in the Valsartan group,with differences being significant(P<0.05).After treatment,the red blood cell aggregation indexes,plasma viscosity,low-shear viscosity,and high-shear viscosity in the two groups were decreased when compared with those before treatment,and the values of the above indicators in the Kunxian Capsules group were lower than those in the Valsartan group,with differences being significant(P<0.05).The total effective rate in the Kunxian Capsules group was 93.33%,and 80.00%in the Valsartan group,with the difference being significant(P<

关 键 词：糖尿病肾病 昆仙胶囊 缬沙坦 肾间质纤维化 炎症因子 血液流变学 

分 类 号：R587.2[医药卫生—内分泌]